library(tidyverse)
library(here)
library(readxl)
library(janitor)
library(gtsummary)initialization_att1r_projectg
Quarto
Positive vs non-positive
| Characteristic | Overall N = 461 |
negative and at risk N = 351 |
positive N = 111 |
p-value2 |
|---|---|---|---|---|
| i_rae_sheet_1_n | 2 (1, 3) | 2 (1, 3) | 1 (1, 3) | 0.5 |
| at1r_interpretation_merged | <0.001 | |||
| at risk | 13 (28%) | 13 (37%) | 0 (0%) | |
| negative | 22 (48%) | 22 (63%) | 0 (0%) | |
| positive | 11 (24%) | 0 (0%) | 11 (100%) | |
| death_sheet_1 | 15 (33%) | 13 (38%) | 2 (18%) | 0.3 |
| hf_baseline | 8 (17%) | 5 (14%) | 3 (27%) | 0.4 |
| hf_outcome | 0.6 | |||
| 0 | 32 (70%) | 23 (66%) | 9 (82%) | |
| 1 | 13 (28%) | 11 (31%) | 2 (18%) | |
| 1 (recovered then HFrEF after ICI) | 1 (2.2%) | 1 (2.9%) | 0 (0%) | |
| arrthythmia_baseline | >0.9 | |||
| 0 | 30 (65%) | 23 (66%) | 7 (64%) | |
| 1 | 16 (35%) | 12 (34%) | 4 (36%) | |
| arrhythmia_outcome | >0.9 | |||
| 0 | 25 (54%) | 19 (54%) | 6 (55%) | |
| 1 | 21 (46%) | 16 (46%) | 5 (45%) | |
| acei_arb | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| aldactone | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| sglt2 | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| beta_blocker | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| myocarditis_severty_adjudication | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| immuno_esc_prolonged | 25 (58%) | 17 (50%) | 8 (89%) | 0.057 |
| number_non_hla_positive_beads_sheet_1 | 4 (1, 12) | 4 (1, 8) | 23 (15, 29) | 0.004 |
| age_of_time_of_sample_sheet_4 | 75 (68, 79) | 74 (65, 78) | 77 (73, 81) | 0.2 |
| race_sheet_4 | 0.3 | |||
| black/aa | 5 (11%) | 5 (14%) | 0 (0%) | |
| white | 41 (89%) | 30 (86%) | 11 (100%) | |
| gender_1_female | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| ethnicity_sheet_4 | 0.2 | |||
| hispanic/latinx | 1 (2.2%) | 0 (0%) | 1 (9.1%) | |
| not hispanic/latinx | 45 (98%) | 35 (100%) | 10 (91%) | |
| metastatic_sheet_4 | 11 (79%) | 9 (75%) | 2 (100%) | >0.9 |
| htn_sheet_4 | 43 (93%) | 34 (97%) | 9 (82%) | 0.14 |
| hld_sheet_4 | 37 (80%) | 27 (77%) | 10 (91%) | 0.4 |
| cad_sheet_4 | 28 (61%) | 18 (51%) | 10 (91%) | 0.032 |
| diabetes_sheet_4 | 10 (22%) | 9 (26%) | 1 (9.1%) | 0.4 |
| hf_sheet_4 | 15 (33%) | 11 (31%) | 4 (36%) | >0.9 |
| valve_sheet_4 | 2 (4.3%) | 2 (5.7%) | 0 (0%) | >0.9 |
| ipi_sheet_4 | 11 (24%) | 7 (20%) | 4 (36%) | 0.4 |
| nivo_sheet_4 | 16 (35%) | 12 (34%) | 4 (36%) | >0.9 |
| pembro_sheet_4 | 25 (54%) | 18 (51%) | 7 (64%) | 0.5 |
| durva_sheet_4 | 5 (11%) | 3 (8.6%) | 2 (18%) | 0.6 |
| atezo_sheet_4 | 6 (13%) | 5 (14%) | 1 (9.1%) | >0.9 |
| days_from_initial_exposure_of_ici_to_presentation_sheet_4 | 75 (33, 333) | 57 (33, 194) | 145 (50, 1,009) | 0.15 |
| pulse_dose_steroids_sheet_4 | 42 (93%) | 33 (97%) | 9 (82%) | 0.14 |
| steroid_pulse_prolonged | 22 (49%) | 16 (47%) | 6 (55%) | 0.7 |
| mmf_sheet_4 | 25 (56%) | 19 (56%) | 6 (55%) | >0.9 |
| abatacept_sheet_4 | 17 (38%) | 13 (38%) | 4 (36%) | >0.9 |
| ivig_sheet_4 | 10 (22%) | 6 (18%) | 4 (36%) | 0.2 |
| infliximab_sheet_4 | 2 (4.4%) | 2 (5.9%) | 0 (0%) | >0.9 |
| tofacitinib_sheet_4 | 11 (24%) | 10 (29%) | 1 (9.1%) | 0.2 |
| immune_suppression_escalation_1_0_sheet_4 | 25 (56%) | 17 (50%) | 8 (73%) | 0.3 |
| multiple_escalations_sheet_4 | 1.00 (0.00, 1.00) | 0.50 (0.00, 1.00) | 1.00 (0.00, 2.00) | 0.2 |
| lvef_sheet_4 | 58 (48, 63) | 54 (39, 61) | 64 (58, 64) | 0.036 |
| rvef_sheet_4 | 49 (45, 56) | 49 (44, 52) | 58 (50, 66) | 0.078 |
| ischemic_nonischemic_both_sheet_4 | 0.6 | |||
| 23 (61%) | 17 (59%) | 6 (67%) | ||
| 0 | 1 (2.6%) | 1 (3.4%) | 0 (0%) | |
| both | 2 (5.3%) | 1 (3.4%) | 1 (11%) | |
| nonischemic | 12 (32%) | 10 (34%) | 2 (22%) | |
| other_irae_sheet_4 | 0.4 | |||
| 44 (96%) | 34 (97%) | 10 (91%) | ||
| myositis, MG myocarditis | 1 (2.2%) | 0 (0%) | 1 (9.1%) | |
| pneumonitis | 1 (2.2%) | 1 (2.9%) | 0 (0%) | |
| t1_52_matt_cmr | 1,012 (957, 1,016) | 1,015 (992, 1,016) | 946 (882, 1,011) | 0.14 |
| ecv_matt_cmr | 0.6 | |||
| 21 | 1 (11%) | 1 (14%) | 0 (0%) | |
| 23 | 1 (11%) | 1 (14%) | 0 (0%) | |
| 26 | 1 (11%) | 0 (0%) | 1 (50%) | |
| 27 | 1 (11%) | 1 (14%) | 0 (0%) | |
| 31 | 1 (11%) | 1 (14%) | 0 (0%) | |
| 34 | 1 (11%) | 1 (14%) | 0 (0%) | |
| 36 | 2 (22%) | 2 (29%) | 0 (0%) | |
| 40 | 1 (11%) | 0 (0%) | 1 (50%) | |
| t2_0_normal1_elevated_matt_cmr | 19 (61%) | 14 (61%) | 5 (63%) | >0.9 |
| lge_burden_matt_cmr | 7 (3, 11) | 6 (0, 9) | 11 (4, 15) | 0.046 |
| cm_outcome | ||||
| 1 | 14 (100%) | 12 (100%) | 2 (100%) | |
| lvef_56_matt_cmr | 59 (51, 64) | 58 (44, 63) | 64 (58, 68) | 0.11 |
| rvef_57_matt_cmr | 52 (47, 57) | 51 (48, 54) | 52 (45, 58) | 0.4 |
| lv_wall_thickness_ap_matt_cmr | 10.00 (8.00, 11.00) | 10.00 (8.00, 11.00) | 9.00 (6.00, 11.00) | 0.6 |
| lv_wall_thickness_pl_matt_cmr | 8.00 (7.00, 9.50) | 8.00 (6.00, 9.00) | 9.00 (7.00, 11.00) | 0.15 |
| global_radial_str_matt_cmr | 26 (21, 36) | 23 (20, 33) | 34 (22, 36) | 0.3 |
| global_circ_strain_matt_cmr | -16.0 (-19.9, -13.6) | -15.2 (-20.1, -13.3) | -18.4 (-19.8, -14.8) | 0.4 |
| gls_matt_cmr | -13.5 (-16.6, -10.7) | -13.1 (-16.6, -10.0) | -14.6 (-15.5, -10.8) | 0.7 |
| abnormal_gls | 32 (84%) | 23 (85%) | 9 (82%) | >0.9 |
| mapse_anterior_matt_cmr | 9.9 (7.3, 12.3) | 9.7 (6.3, 13.4) | 10.1 (7.3, 12.2) | >0.9 |
| mapse_inferior_matt_cmr | 11.2 (9.7, 14.5) | 12.3 (9.8, 14.6) | 10.5 (9.7, 12.9) | 0.5 |
| mapse_mean_matt_cmr | 10.2 (8.6, 12.5) | 10.2 (8.2, 13.2) | 10.9 (8.9, 12.0) | >0.9 |
| remove_variavle | NA (NA, NA) | NA (NA, NA) | NA (NA, NA) | |
| new_arrythmia | 18 (39%) | 13 (37%) | 5 (45%) | 0.7 |
| 1 Median (Q1, Q3); n (%) | ||||
| 2 Wilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test; NA | ||||
Negative vs non-negative
| Characteristic | Overall N = 461 |
negative N = 221 |
positive and at risk N = 241 |
p-value2 |
|---|---|---|---|---|
| i_rae_sheet_1_n | 2 (1, 3) | 1 (1, 2) | 2 (1, 3) | 0.3 |
| at1r_interpretation_merged | <0.001 | |||
| at risk | 13 (28%) | 0 (0%) | 13 (54%) | |
| negative | 22 (48%) | 22 (100%) | 0 (0%) | |
| positive | 11 (24%) | 0 (0%) | 11 (46%) | |
| death_sheet_1 | 15 (33%) | 9 (41%) | 6 (26%) | 0.3 |
| hf_baseline | 8 (17%) | 3 (14%) | 5 (21%) | 0.7 |
| hf_outcome | 0.3 | |||
| 0 | 32 (70%) | 14 (64%) | 18 (75%) | |
| 1 | 13 (28%) | 8 (36%) | 5 (21%) | |
| 1 (recovered then HFrEF after ICI) | 1 (2.2%) | 0 (0%) | 1 (4.2%) | |
| arrthythmia_baseline | 0.8 | |||
| 0 | 30 (65%) | 14 (64%) | 16 (67%) | |
| 1 | 16 (35%) | 8 (36%) | 8 (33%) | |
| arrhythmia_outcome | 0.5 | |||
| 0 | 25 (54%) | 13 (59%) | 12 (50%) | |
| 1 | 21 (46%) | 9 (41%) | 12 (50%) | |
| acei_arb | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| aldactone | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| sglt2 | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| beta_blocker | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| myocarditis_severty_adjudication | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| immuno_esc_prolonged | 25 (58%) | 10 (48%) | 15 (68%) | 0.2 |
| number_non_hla_positive_beads_sheet_1 | 4 (1, 12) | 1 (1, 5) | 10 (4, 16) | 0.024 |
| age_of_time_of_sample_sheet_4 | 75 (68, 79) | 75 (69, 78) | 75 (65, 79) | >0.9 |
| race_sheet_4 | 0.2 | |||
| black/aa | 5 (11%) | 4 (18%) | 1 (4.2%) | |
| white | 41 (89%) | 18 (82%) | 23 (96%) | |
| gender_1_female | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| ethnicity_sheet_4 | >0.9 | |||
| hispanic/latinx | 1 (2.2%) | 0 (0%) | 1 (4.2%) | |
| not hispanic/latinx | 45 (98%) | 22 (100%) | 23 (96%) | |
| metastatic_sheet_4 | 11 (79%) | 6 (67%) | 5 (100%) | 0.3 |
| htn_sheet_4 | 43 (93%) | 22 (100%) | 21 (88%) | 0.2 |
| hld_sheet_4 | 37 (80%) | 16 (73%) | 21 (88%) | 0.3 |
| cad_sheet_4 | 28 (61%) | 13 (59%) | 15 (63%) | 0.8 |
| diabetes_sheet_4 | 10 (22%) | 7 (32%) | 3 (13%) | 0.2 |
| hf_sheet_4 | 15 (33%) | 7 (32%) | 8 (33%) | >0.9 |
| valve_sheet_4 | 2 (4.3%) | 2 (9.1%) | 0 (0%) | 0.2 |
| ipi_sheet_4 | 11 (24%) | 3 (14%) | 8 (33%) | 0.12 |
| nivo_sheet_4 | 16 (35%) | 6 (27%) | 10 (42%) | 0.3 |
| pembro_sheet_4 | 25 (54%) | 13 (59%) | 12 (50%) | 0.5 |
| durva_sheet_4 | 5 (11%) | 2 (9.1%) | 3 (13%) | >0.9 |
| atezo_sheet_4 | 6 (13%) | 3 (14%) | 3 (13%) | >0.9 |
| days_from_initial_exposure_of_ici_to_presentation_sheet_4 | 75 (33, 333) | 67 (35, 239) | 75 (31, 594) | 0.8 |
| pulse_dose_steroids_sheet_4 | 42 (93%) | 20 (95%) | 22 (92%) | >0.9 |
| steroid_pulse_prolonged | 22 (49%) | 11 (52%) | 11 (46%) | 0.7 |
| mmf_sheet_4 | 25 (56%) | 13 (62%) | 12 (50%) | 0.4 |
| abatacept_sheet_4 | 17 (38%) | 9 (43%) | 8 (33%) | 0.5 |
| ivig_sheet_4 | 10 (22%) | 4 (19%) | 6 (25%) | 0.7 |
| infliximab_sheet_4 | 2 (4.4%) | 2 (9.5%) | 0 (0%) | 0.2 |
| tofacitinib_sheet_4 | 11 (24%) | 6 (29%) | 5 (21%) | 0.5 |
| immune_suppression_escalation_1_0_sheet_4 | 25 (56%) | 10 (48%) | 15 (63%) | 0.3 |
| multiple_escalations_sheet_4 | 1.00 (0.00, 1.00) | 0.00 (0.00, 1.00) | 1.00 (0.00, 1.00) | 0.4 |
| lvef_sheet_4 | 58 (48, 63) | 54 (41, 59) | 58 (48, 64) | 0.2 |
| rvef_sheet_4 | 49 (45, 56) | 46 (39, 50) | 52 (49, 63) | 0.015 |
| ischemic_nonischemic_both_sheet_4 | 0.5 | |||
| 23 (61%) | 12 (67%) | 11 (55%) | ||
| 0 | 1 (2.6%) | 1 (5.6%) | 0 (0%) | |
| both | 2 (5.3%) | 0 (0%) | 2 (10%) | |
| nonischemic | 12 (32%) | 5 (28%) | 7 (35%) | |
| other_irae_sheet_4 | 0.7 | |||
| 44 (96%) | 21 (95%) | 23 (96%) | ||
| myositis, MG myocarditis | 1 (2.2%) | 0 (0%) | 1 (4.2%) | |
| pneumonitis | 1 (2.2%) | 1 (4.5%) | 0 (0%) | |
| t1_52_matt_cmr | 1,012 (957, 1,016) | 1,014 (992, 1,016) | 964 (938, 1,069) | 0.6 |
| ecv_matt_cmr | 0.4 | |||
| 21 | 1 (11%) | 1 (25%) | 0 (0%) | |
| 23 | 1 (11%) | 0 (0%) | 1 (20%) | |
| 26 | 1 (11%) | 0 (0%) | 1 (20%) | |
| 27 | 1 (11%) | 1 (25%) | 0 (0%) | |
| 31 | 1 (11%) | 0 (0%) | 1 (20%) | |
| 34 | 1 (11%) | 0 (0%) | 1 (20%) | |
| 36 | 2 (22%) | 2 (50%) | 0 (0%) | |
| 40 | 1 (11%) | 0 (0%) | 1 (20%) | |
| t2_0_normal1_elevated_matt_cmr | 19 (61%) | 9 (56%) | 10 (67%) | 0.6 |
| lge_burden_matt_cmr | 7 (3, 11) | 6 (0, 9) | 9 (4, 13) | 0.11 |
| cm_outcome | ||||
| 1 | 14 (100%) | 6 (100%) | 8 (100%) | |
| lvef_56_matt_cmr | 59 (51, 64) | 60 (53, 63) | 58 (50, 68) | 0.5 |
| rvef_57_matt_cmr | 52 (47, 57) | 52 (48, 54) | 50 (45, 58) | >0.9 |
| lv_wall_thickness_ap_matt_cmr | 10.00 (8.00, 11.00) | 10.00 (8.00, 11.00) | 11.00 (8.00, 11.00) | 0.3 |
| lv_wall_thickness_pl_matt_cmr | 8.00 (7.00, 9.50) | 7.50 (6.00, 9.00) | 8.00 (7.00, 10.00) | 0.2 |
| global_radial_str_matt_cmr | 26 (21, 36) | 29 (22, 36) | 23 (21, 36) | 0.9 |
| global_circ_strain_matt_cmr | -16.0 (-19.9, -13.6) | -17.9 (-20.3, -13.0) | -15.2 (-19.6, -14.2) | 0.8 |
| gls_matt_cmr | -13.5 (-16.6, -10.7) | -14.7 (-17.9, -11.3) | -12.1 (-15.1, -9.6) | 0.2 |
| abnormal_gls | 32 (84%) | 14 (82%) | 18 (86%) | >0.9 |
| mapse_anterior_matt_cmr | 9.9 (7.3, 12.3) | 10.3 (5.9, 14.4) | 9.7 (7.3, 11.7) | 0.6 |
| mapse_inferior_matt_cmr | 11.2 (9.7, 14.5) | 12.5 (10.0, 14.6) | 10.6 (8.9, 13.3) | 0.2 |
| mapse_mean_matt_cmr | 10.2 (8.6, 12.5) | 11.6 (8.9, 14.0) | 10.0 (8.6, 12.0) | 0.3 |
| remove_variavle | NA (NA, NA) | NA (NA, NA) | NA (NA, NA) | |
| new_arrythmia | 18 (39%) | 8 (36%) | 10 (42%) | 0.7 |
| 1 Median (Q1, Q3); n (%) | ||||
| 2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test; NA | ||||
Removed all “at risk”
| Characteristic | Overall N = 331 |
negative N = 221 |
positive N = 111 |
p-value2 |
|---|---|---|---|---|
| i_rae_sheet_1_n | 1 (1, 2) | 1 (1, 2) | 1 (1, 3) | >0.9 |
| at1r_interpretation_merged | <0.001 | |||
| negative | 22 (67%) | 22 (100%) | 0 (0%) | |
| positive | 11 (33%) | 0 (0%) | 11 (100%) | |
| death_sheet_1 | 11 (33%) | 9 (41%) | 2 (18%) | 0.3 |
| hf_baseline | 6 (18%) | 3 (14%) | 3 (27%) | 0.4 |
| hf_outcome | 0.4 | |||
| 0 | 23 (70%) | 14 (64%) | 9 (82%) | |
| 1 | 10 (30%) | 8 (36%) | 2 (18%) | |
| arrthythmia_baseline | >0.9 | |||
| 0 | 21 (64%) | 14 (64%) | 7 (64%) | |
| 1 | 12 (36%) | 8 (36%) | 4 (36%) | |
| arrhythmia_outcome | >0.9 | |||
| 0 | 19 (58%) | 13 (59%) | 6 (55%) | |
| 1 | 14 (42%) | 9 (41%) | 5 (45%) | |
| acei_arb | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| aldactone | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| sglt2 | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| beta_blocker | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| myocarditis_severty_adjudication | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| immuno_esc_prolonged | 18 (60%) | 10 (48%) | 8 (89%) | 0.049 |
| number_non_hla_positive_beads_sheet_1 | 0.2 | |||
| 0 | 1 (9.1%) | 1 (14%) | 0 (0%) | |
| 1 | 3 (27%) | 3 (43%) | 0 (0%) | |
| 4 | 1 (9.1%) | 1 (14%) | 0 (0%) | |
| 5 | 1 (9.1%) | 1 (14%) | 0 (0%) | |
| 8 | 1 (9.1%) | 1 (14%) | 0 (0%) | |
| 12 | 1 (9.1%) | 0 (0%) | 1 (25%) | |
| 17 | 1 (9.1%) | 0 (0%) | 1 (25%) | |
| 28 | 1 (9.1%) | 0 (0%) | 1 (25%) | |
| 29 | 1 (9.1%) | 0 (0%) | 1 (25%) | |
| age_of_time_of_sample_sheet_4 | 75 (69, 79) | 75 (69, 78) | 77 (73, 81) | 0.3 |
| race_sheet_4 | 0.3 | |||
| black/aa | 4 (12%) | 4 (18%) | 0 (0%) | |
| white | 29 (88%) | 18 (82%) | 11 (100%) | |
| gender_1_female | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| ethnicity_sheet_4 | 0.3 | |||
| hispanic/latinx | 1 (3.0%) | 0 (0%) | 1 (9.1%) | |
| not hispanic/latinx | 32 (97%) | 22 (100%) | 10 (91%) | |
| metastatic_sheet_4 | 8 (73%) | 6 (67%) | 2 (100%) | >0.9 |
| htn_sheet_4 | 31 (94%) | 22 (100%) | 9 (82%) | 0.10 |
| hld_sheet_4 | 26 (79%) | 16 (73%) | 10 (91%) | 0.4 |
| cad_sheet_4 | 23 (70%) | 13 (59%) | 10 (91%) | 0.11 |
| diabetes_sheet_4 | 8 (24%) | 7 (32%) | 1 (9.1%) | 0.2 |
| hf_sheet_4 | 11 (33%) | 7 (32%) | 4 (36%) | >0.9 |
| valve_sheet_4 | 2 (6.1%) | 2 (9.1%) | 0 (0%) | 0.5 |
| ipi_sheet_4 | 7 (21%) | 3 (14%) | 4 (36%) | 0.2 |
| nivo_sheet_4 | 10 (30%) | 6 (27%) | 4 (36%) | 0.7 |
| pembro_sheet_4 | 20 (61%) | 13 (59%) | 7 (64%) | >0.9 |
| durva_sheet_4 | 4 (12%) | 2 (9.1%) | 2 (18%) | 0.6 |
| atezo_sheet_4 | 4 (12%) | 3 (14%) | 1 (9.1%) | >0.9 |
| days_from_initial_exposure_of_ici_to_presentation_sheet_4 | 82 (35, 455) | 67 (35, 239) | 145 (50, 1,009) | 0.2 |
| pulse_dose_steroids_sheet_4 | 29 (91%) | 20 (95%) | 9 (82%) | 0.3 |
| steroid_pulse_prolonged | 17 (53%) | 11 (52%) | 6 (55%) | >0.9 |
| mmf_sheet_4 | 19 (59%) | 13 (62%) | 6 (55%) | 0.7 |
| abatacept_sheet_4 | 13 (41%) | 9 (43%) | 4 (36%) | >0.9 |
| ivig_sheet_4 | 8 (25%) | 4 (19%) | 4 (36%) | 0.4 |
| infliximab_sheet_4 | 2 (6.3%) | 2 (9.5%) | 0 (0%) | 0.5 |
| tofacitinib_sheet_4 | 7 (22%) | 6 (29%) | 1 (9.1%) | 0.4 |
| immune_suppression_escalation_1_0_sheet_4 | 18 (56%) | 10 (48%) | 8 (73%) | 0.3 |
| multiple_escalations_sheet_4 | 1.00 (0.00, 1.00) | 0.00 (0.00, 1.00) | 1.00 (0.00, 2.00) | 0.2 |
| lvef_sheet_4 | 58 (54, 62) | 54 (41, 59) | 64 (58, 64) | 0.023 |
| rvef_sheet_4 | 49 (44, 52) | 46 (39, 50) | 58 (50, 66) | 0.040 |
| ischemic_nonischemic_both_sheet_4 | 0.7 | |||
| 18 (67%) | 12 (67%) | 6 (67%) | ||
| 0 | 1 (3.7%) | 1 (5.6%) | 0 (0%) | |
| both | 1 (3.7%) | 0 (0%) | 1 (11%) | |
| nonischemic | 7 (26%) | 5 (28%) | 2 (22%) | |
| other_irae_sheet_4 | 0.6 | |||
| 31 (94%) | 21 (95%) | 10 (91%) | ||
| myositis, MG myocarditis | 1 (3.0%) | 0 (0%) | 1 (9.1%) | |
| pneumonitis | 1 (3.0%) | 1 (4.5%) | 0 (0%) | |
| t1_52_matt_cmr | 1,002 (953, 1,016) | 1,014 (992, 1,016) | 946 (882, 1,011) | 0.3 |
| ecv_matt_cmr | 0.5 | |||
| 21 | 1 (17%) | 1 (25%) | 0 (0%) | |
| 26 | 1 (17%) | 0 (0%) | 1 (50%) | |
| 27 | 1 (17%) | 1 (25%) | 0 (0%) | |
| 36 | 2 (33%) | 2 (50%) | 0 (0%) | |
| 40 | 1 (17%) | 0 (0%) | 1 (50%) | |
| t2_0_normal1_elevated_matt_cmr | 14 (58%) | 9 (56%) | 5 (63%) | >0.9 |
| lge_burden_matt_cmr | 7 (0, 11) | 6 (0, 9) | 11 (4, 15) | 0.049 |
| cm_outcome | ||||
| 1 | 8 (100%) | 6 (100%) | 2 (100%) | |
| lvef_56_matt_cmr | 60 (54, 64) | 60 (53, 63) | 64 (58, 68) | 0.14 |
| rvef_57_matt_cmr | 52 (48, 57) | 52 (48, 54) | 52 (45, 58) | 0.5 |
| lv_wall_thickness_ap_matt_cmr | 10.00 (7.00, 11.00) | 10.00 (8.00, 11.00) | 9.00 (6.00, 11.00) | >0.9 |
| lv_wall_thickness_pl_matt_cmr | 8.00 (7.00, 9.00) | 7.50 (6.00, 9.00) | 9.00 (7.00, 11.00) | 0.12 |
| global_radial_str_matt_cmr | 29 (22, 36) | 29 (22, 36) | 34 (22, 36) | 0.6 |
| global_circ_strain_matt_cmr | -18.0 (-19.9, -14.6) | -17.9 (-20.3, -13.0) | -18.4 (-19.8, -14.8) | 0.8 |
| gls_matt_cmr | -14.7 (-16.7, -11.3) | -14.7 (-17.9, -11.3) | -14.6 (-15.5, -10.8) | 0.7 |
| abnormal_gls | 23 (82%) | 14 (82%) | 9 (82%) | >0.9 |
| mapse_anterior_matt_cmr | 10.2 (7.3, 12.4) | 10.3 (5.9, 14.4) | 10.1 (7.3, 12.2) | 0.9 |
| mapse_inferior_matt_cmr | 12.3 (9.9, 14.5) | 12.5 (10.0, 14.6) | 10.5 (9.7, 12.9) | 0.3 |
| mapse_mean_matt_cmr | 10.9 (8.9, 12.8) | 11.6 (8.9, 14.0) | 10.9 (8.9, 12.0) | 0.7 |
| remove_variavle | NA (NA, NA) | NA (NA, NA) | NA (NA, NA) | |
| new_arrythmia | 13 (39%) | 8 (36%) | 5 (45%) | 0.7 |
| 1 Median (Q1, Q3); n (%) | ||||
| 2 Wilcoxon rank sum test; Fisher’s exact test; NA; Pearson’s Chi-squared test; Wilcoxon rank sum exact test | ||||